Claudio Dansky Ullmann

1.4k total citations
26 papers, 797 citations indexed

About

Claudio Dansky Ullmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cell Biology. According to data from OpenAlex, Claudio Dansky Ullmann has authored 26 papers receiving a total of 797 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Cell Biology. Recurrent topics in Claudio Dansky Ullmann's work include Microtubule and mitosis dynamics (7 papers), Cancer-related Molecular Pathways (6 papers) and Lung Cancer Research Studies (4 papers). Claudio Dansky Ullmann is often cited by papers focused on Microtubule and mitosis dynamics (7 papers), Cancer-related Molecular Pathways (6 papers) and Lung Cancer Research Studies (4 papers). Claudio Dansky Ullmann collaborates with scholars based in United States, Japan and France. Claudio Dansky Ullmann's co-authors include A. Craig Lockhart, Jaafar Bennouna, Bohuslav Melichar, Antoine Adenis, E. Claire Dees, Omar Kayaleh, Bin Zhang, Angela DeMichele, Petr Zatloukal and Radka Obermannová and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Claudio Dansky Ullmann

26 papers receiving 783 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudio Dansky Ullmann United States	14	398	275	219	139	136	26	797
Volkert B. Wreesmann United States	22	424 1.1×	440 1.6×	357 1.6×	413 3.0×	131 1.0×	32	1.4k
Andrew P. Stein United States	12	273 0.7×	189 0.7×	168 0.8×	227 1.6×	117 0.9×	24	719
G. B. Snow Netherlands	12	338 0.8×	286 1.0×	302 1.4×	195 1.4×	112 0.8×	17	788
Françoise Drusch France	14	544 1.4×	215 0.8×	133 0.6×	114 0.8×	195 1.4×	17	924
A. J. M. Balm Netherlands	11	416 1.0×	279 1.0×	176 0.8×	113 0.8×	175 1.3×	22	720
Dong-Hua Luo China	15	379 1.0×	475 1.7×	388 1.8×	258 1.9×	179 1.3×	24	1.1k
Hua-Qing Min China	9	314 0.8×	237 0.9×	436 2.0×	323 2.3×	180 1.3×	13	787
Ulf K. Zätterström Sweden	13	233 0.6×	273 1.0×	272 1.2×	156 1.1×	168 1.2×	25	670
Charles N. Weber United States	9	155 0.4×	324 1.2×	51 0.2×	130 0.9×	115 0.8×	19	634
Dale Butterfoss United States	3	273 0.7×	550 2.0×	171 0.8×	56 0.4×	97 0.7×	5	786

Countries citing papers authored by Claudio Dansky Ullmann

Since Specialization

Citations

This map shows the geographic impact of Claudio Dansky Ullmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio Dansky Ullmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio Dansky Ullmann more than expected).

Fields of papers citing papers by Claudio Dansky Ullmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudio Dansky Ullmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio Dansky Ullmann. The network helps show where Claudio Dansky Ullmann may publish in the future.

Co-authorship network of co-authors of Claudio Dansky Ullmann

This figure shows the co-authorship network connecting the top 25 collaborators of Claudio Dansky Ullmann. A scholar is included among the top collaborators of Claudio Dansky Ullmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudio Dansky Ullmann. Claudio Dansky Ullmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Annunziata, Christina M., Armin Ghobadi, Eduardo J. Pennella, et al.. (2020). Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.. Journal of Clinical Oncology. 38(15_suppl). 3014–3014. 25 indexed citations

Ghobadi, Armin, Premal H. Thaker, David Weng, et al.. (2019). Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy. Cancer Research. 79(13_Supplement). CT159–CT159. 1 indexed citations

Zhou, Xiaofei, et al.. (2018). Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. Investigational New Drugs. 37(4). 666–673. 4 indexed citations

Sullivan, Ryan J., David S. Hong, Anthony W. Tolcher, et al.. (2018). Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 3013–3013. 51 indexed citations

Owonikoko, Taofeek K., Kristiaan Nackaerts, Tibor Csőszi, et al.. (2017). OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 12(1). S261–S262. 17 indexed citations

Falchook, Gerald S., Xiaofei Zhou, Karthik Venkatakrishnan, et al.. (2015). Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R&D. 16(1). 45–52. 9 indexed citations

Melichar, Bohuslav, Antoine Adenis, A. Craig Lockhart, et al.. (2015). Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet Oncology. 16(4). 395–405. 200 indexed citations

Falchook, Gerald S., Karthik Venkatakrishnan, John Sarantopoulos, et al.. (2015). Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 53(7). 563–572. 5 indexed citations

Malik, Shakun, Richard Pazdur, Jeffrey S. Abrams, et al.. (2014). Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer. Journal of Thoracic Oncology. 9(10). 1443–1448. 18 indexed citations

10.

Özcan, Muhıt, Andrei R. Shustov, Xiaofei Zhou, et al.. (2014). Trial in Progress: Phase 3 Randomized Study of Investigational Drug Alisertib (Mln8237) Vs Investigator'S Choice in Patients (Pts) with Relapsed/Refractory (Rel/Ref) Peripheral T-Cell Lymphoma (Ptcl): the Lumiere Trial. Annals of Oncology. 25. iv339–iv339. 1 indexed citations

11.

Parsons, Helen, Linda C. Harlan, Jennifer L. Stevens, & Claudio Dansky Ullmann. (2014). Treatment of Small Cell Lung Cancer in Academic and Community Settings. The Cancer Journal. 20(2). 97–104. 14 indexed citations

12.

Sarantopoulos, John, Noah M. Hahn, Celestia S. Higano, et al.. (2014). Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 32(4_suppl). 217–217. 3 indexed citations

13.

Coleman, Robert L., A. Roszak, Kian Behbakht, et al.. (2014). Randomized Phase 2 Study of Investigational, Selective Aurora a Kinase Inhibitor Alisertib (Mln8237) with Weekly Paclitaxel Vs Paclitaxel Alone in Patients (Pts) with Recurrent Ovarian Cancer (Oc). Annals of Oncology. 25. iv305–iv305. 4 indexed citations

14.

Kelly, Kevin R., Daniel O. Persky, Daruka Mahadevan, et al.. (2013). Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood. 122(21). 3027–3027. 7 indexed citations

15.

Ullmann, Claudio Dansky, Linda C. Harlan, Vickie L. Shavers, & Jennifer L. Stevens. (2012). A population‐based study of therapy and survival for patients with head and neck cancer treated in the community. Cancer. 118(18). 4452–4461. 43 indexed citations

16.

Harris, Pamela Jo, Giovanna Speranza, & Claudio Dansky Ullmann. (2012). Targeting embryonic signaling pathways in cancer therapy. Expert Opinion on Therapeutic Targets. 16(1). 131–145. 33 indexed citations

17.

Ullmann, Claudio Dansky. (2010). Cancer Stem Cells and Targeting Embryonic Signaling Pathways. Journal of Thoracic Oncology. 5(12). S492–S494. 1 indexed citations

18.

Adelstein, David J., John A. Ridge, Maura L. Gillison, et al.. (2009). Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.. Head & Neck. 31(11). 1393–1422. 211 indexed citations

19.

Ullmann, Claudio Dansky, Carol Nieroda, Diane Eggensperger, et al.. (1993). Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.. PubMed. 53(3). 600–8. 47 indexed citations

20.

Ullmann, Claudio Dansky, et al.. (1992). Interleukin-6 Increases Carcinoembryonic Antigen and Histocompatibility Leukocyte Antigen Expression on the Surface of Human Colorectal Carcinoma Cells. Journal of Immunotherapy. 12(4). 231–241. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact